<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02734238</url>
  </required_header>
  <id_info>
    <org_study_id>PBRC 2015-063</org_study_id>
    <nct_id>NCT02734238</nct_id>
  </id_info>
  <brief_title>Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery</brief_title>
  <acronym>OPS</acronym>
  <official_title>Physiological and Psychological Effects of Testosterone During Severe Energy Deficit and Recovery: a Randomized, Placebo Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pennington Biomedical Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>United States Army Research Institute of Environmental Medicine</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>MyoSyntax</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Defence Research and Development Canada</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>United States Department of Defense</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
  </sponsors>
  <source>Pennington Biomedical Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to determine whether maintaining a eugonadal state, during
      severe, sustained energy deficit, attenuates physiological decrements, particularly the loss
      of lean body mass, and maintains mental performance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study will enroll up to 60 physically active men in a 3-phase randomized,
      placebo-controlled trial. After completing a 14-day (free-living, phase 1), energy-adequate,
      diet-acclimation phase (protein, 1.6 g∙kg-1∙d-1; fat 30% total energy intake, with remaining
      energy derived from carbohydrate), participants will be randomized to one of two experimental
      groups and undergo a 28-day (live-in, phase 2), 55% energy deficit phase: energy deficit
      alone (DEF) or energy deficit + exogenous testosterone (DEF+TEST). Recovery (free-living,
      phase 3) will be assessed after completing phase 2 to determine when body mass has been
      recovered within ± 2.5% of initial body mass (duration will vary, 42-day maximum for phase
      3). This study will delineate the contribution of testosterone declines from the physical and
      mental demands encountered by Warfighters during military training and combat operations on
      complex markers of physiological and psychological status, addressing a direct, consistently
      observed, gap in knowledge.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 2016</start_date>
  <completion_date type="Actual">December 2017</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Total Body Mass</measure>
    <time_frame>baseline; days 11, 28, 39, 53; and through study completion, up to day 85</time_frame>
    <description>Height will be measured using a stadiometer. Weight will be measured using a calibrated digital scale. Body composition will be determined using dual-energy X-ray absorptiometry. These data will be used to calculate lean body mass, fat mass, bone mineral content, bone mineral density, and total body tissue mass.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Skeletal Muscle Mass</measure>
    <time_frame>Days 11, 39, and 53; and upon return to initial body weight, up to day 85</time_frame>
    <description>Participants will provide a fasting urine sample prior to ingesting a single, 60 mg dose (capsule) of creatine (methyl-d3) on days 11, 39, 53, and at study completion (return to initial body weight, up to day 85). Fasting urine samples will be collected 48 and 72 hours after each creatine pill ingestion.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Body Water Enrichment</measure>
    <time_frame>from baseline through day 42</time_frame>
    <description>Participants will consume heavy water (70%) from day 0 through day 42. Body water enrichment will be determined from blood collected on days 14, 28, and 42 and saliva samples collected on days 3, 7, 11, 15, 19, 23, 27, 31, 35 and 39.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Protein Synthesis Rates</measure>
    <time_frame>Days 14, 28, 42</time_frame>
    <description>Muscle biopsy samples of the vastus lateralis will be collected while participants are under local anesthesia (1% lidocaine) using a 5-mm Bergstrom needle with manual suction on days 14, 28, and 42. Participants will undergo three muscle biopsy procedures taken from the same incision (pre-exercise, 60-min and 360-min post-exercise) on days 14 and 42. One muscle biopsy will be performed on day 28 on the same leg sampled on day 14, with the incision ~7 cm apart from the incision made on day 14. Up to 250 mg of tissue will be collected with each procedure. Participants will be fasted for pre-exercise and 60-min post-exercise biopsies. A segment of each muscle biopsy sample will be used for muscle proteomics and molecular analyses.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of Proteome Dynamics</measure>
    <time_frame>Days 14, 28, 42</time_frame>
    <description>Muscle samples will be analyzed to calculate peptide elemental composition and isotopomer patterns.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Fiber Type (fast/slow)</measure>
    <time_frame>days 14 and 42</time_frame>
    <description>The proportion of muscle fiber types (type II/fast-twitch/strength and type I/slow-twitch/endurance) will be measured at day 14 and again at day 42 for both treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Muscle Cross-Sectional Area</measure>
    <time_frame>days 14 and 42</time_frame>
    <description>Cross-sectional area for each muscle fiber type (type II/fast-twitch/strength and type I/slow-twitch/endurance) will be measured at day 14 and again at day 42 for each subject to identify muscle wasting based on fiber type. Expression changes will be measured to link wasting with specific cell signaling.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cell-Specific Response In Vitro to Anabolic Agents</measure>
    <time_frame>days 14 and 42</time_frame>
    <description>Expression changes in response to anabolic exposure in vitro will be measured from muscle precursor cells from muscle biopsy segments obtained on days 14 and 42, pre and 360-min post exercise.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Inflammatory Profiles in Blood Derived Cells and Muscle Tissue Derived Leukocytes</measure>
    <time_frame>days 14 and 42</time_frame>
    <description>Blood and muscle derived monocyte/macrophage and T cell subsets will be measured. Cell subsets in blood and muscle will be compared with serum inflammatory factors measured.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of Muscular Strength</measure>
    <time_frame>days 13, 41, 55 and upon return to initial body weight, up to day 85</time_frame>
    <description>Muscular strength will be measured with isometric and isokinetic knee extension tests on days 13, 41, 55, and upon return to initial body weight, up to day 85. A familiarization session will take place on day 0. Isometric quadriceps strength, maximal power and muscular endurance will be quantified using an isokinetic dynamometer (Biodex Medical Systems, Shirley, New York). Isometric muscle strength will be measured at 75° knee flexion. This procedure will be performed three times, each separated by a 30 sec rest period. Maximal muscle strength (maximal voluntary contraction) will be determined from six maximal knee extensions at a fixed speed of 60° per second, while muscular endurance capability will be quantified during 20 repeated maximal knee extensions with movement speed fixed at 180° per second. Unilateral testing will be done on the dominant leg.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of Energy Expenditure</measure>
    <time_frame>days 11, 39 and 53</time_frame>
    <description>Energy expenditure will be measured for a 24-hour period in a metabolic chamber. Energy expenditure will be calculated by indirect calorimetry corrected for urinary nitrogen excretion and respiratory quotient. Energy expenditure will be calculated for the 24-hour period and also partitioned between rest, exercise and sleep.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of Substrate Oxidation</measure>
    <time_frame>days 11, 39 and 53</time_frame>
    <description>Substrate oxidation will be measured for a 24-hour period in a metabolic chamber. Substrate oxidation will be calculated for the 24-hour period and also partitioned between rest, exercise and sleep. Substrate oxidation (carbohydrate, fat, and protein) will be calculated using standard equations.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Minnesota Multiphasic Personality Inventory Scores</measure>
    <time_frame>days 5 and 40</time_frame>
    <description>A psychological assessment will be administered via computer software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Aggression Impulses</measure>
    <time_frame>days 13, 15, 20, 22, 27, 29, 34, 36, 41, 54 and upon return to initial body weight, up to day 85</time_frame>
    <description>Participants will rank statements on the 29-item Buss-Perry Aggression Questionnaire.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mood States</measure>
    <time_frame>days 13, 15, 20, 22, 27, 29, 34, 36, 41, 54 and upon return to initial body weight, up to day 85</time_frame>
    <description>Participants will complete the Profile of Mood States Questionnaire, a 65-item inventory of subjective mood states that is sensitive to a wide variety of nutritional manipulations, environmental factors, sleep loss and subclinical doses of various drugs.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Perceived Hunger and Fullness</measure>
    <time_frame>days 13, 15, 20, 22, 27, 29, 34, 36, 41, 54 and upon return to initial body weight, up to day 85</time_frame>
    <description>Participants will mark on the Satiety Labeled Intensity Magnitude questionnaire their subjective feelings of hunger and fullness.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Willingness to Take Risks</measure>
    <time_frame>days 13, 15, 20, 22, 27, 29, 34, 36, 41, 54 and upon return to initial body weight, up to day 85</time_frame>
    <description>Participants will take the Balloon Analogue Risk Task via computer software to measure willingness to take risks versus &quot;play it safe.&quot; It requires the participant to fill a simulated balloon with air. Points are given for maintaining the flow of air and keeping the volume of the balloon as full as possible. The more expanded the balloon gets, the more points are earned. However, all points are lost if the balloon is over-inflated and pops. The object of this task is to earn as many points as possible by keeping the balloon inflated without popping.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Cooperation</measure>
    <time_frame>days 13, 15, 20, 22, 27, 29, 34, 36, 41, 54 and upon return to initial body weight, up to day 85</time_frame>
    <description>Subjects will participate in the Ultimatum Game, a test of negotiation and cooperation between two people.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Ability to Infer Intentions of Others</measure>
    <time_frame>days 13, 15, 20, 22, 27, 29, 34, 36, 41, 54 and upon return to initial body weight, up to day 85</time_frame>
    <description>Participants will be administered the Reading the Mind in the Eyes Test via computer software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Vigilance</measure>
    <time_frame>days 13, 15, 20, 22, 27, 29, 34, 36, 41, 54 and upon return to initial body weight, up to day 85</time_frame>
    <description>Participants will be administered the Scanning Visual Vigilance Task via computer software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Visual Reaction Time</measure>
    <time_frame>days 13, 15, 20, 22, 27, 29, 34, 36, 41, 54 and upon return to initial body weight, up to day 85</time_frame>
    <description>Participants will be administered the Psychomotor Vigilance Test via computer software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Short-Term Spatial Memory and Pattern Recognition Skills</measure>
    <time_frame>days 13, 15, 20, 22, 27, 29, 34, 36, 41, 54 and upon return to initial body weight, up to day 85</time_frame>
    <description>Participants will take the Matching to Sample test via computer software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Language-Based Logical Reasoning</measure>
    <time_frame>days 13, 15, 20, 22, 27, 29, 34, 36, 41, 54 and upon return to initial body weight, up to day 85</time_frame>
    <description>Participants will take a test adapted from the Baddeley Grammatical Reasoning Test administered via computer software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Rating of Perceived Exertion</measure>
    <time_frame>days 15, 20, 22, 27, 29, 34, 36, and 41</time_frame>
    <description>The Borg Rating of Perceived Exertion Scale will be administered during each exercise test session. The scale will be presented on a video monitor and participants will give a verbal response that will be recorded by an experimenter.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Working Memory Load</measure>
    <time_frame>days 13, 15, 20, 22, 27, 29, 34, 36, 41, 54 and upon return to initial body weight, up to day 85</time_frame>
    <description>Participants will be asked to monitor the identity or location of a series of verbal stimuli (letters) and to indicate when the currently presented stimulus is the same as the one presented &quot;n&quot; trials back (e.g. 0, 1, 2, or 3).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Sleep Cycle</measure>
    <time_frame>continuously from baseline until return to initial body weight, up to day 85</time_frame>
    <description>Actigraphic measures of sleep will be collected throughout the study using wrist-worn monitors.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Risk-Taking Propensity</measure>
    <time_frame>days 5 (approximately), 36, and 55</time_frame>
    <description>Participants will perform the life-cash version of the Gambling Task to assess the propensity for high-risk, high-reward decisions, with differing reward domains (life and cash, respectively). In repeated trials of a simple game, participants are asked to click buttons to choose between a high-risk, high-reward outcome and a low-risk, low-reward outcome. The test will be administered while the participant is inside a magnetic resonance imaging (MRI) scanner. A beltlike respiratory monitor will be affixed around the waist and a pulse oximeter will be clipped onto a finger or toe for physiological monitoring. Headphones are placed over the ears to remove MRI scanner noise and deliver audio stimuli during the task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Retaliatory Aggression Against a Provoking Adversary</measure>
    <time_frame>days 5 (approximately), 36, and 55</time_frame>
    <description>The participant engages in a simple game with an opponent; after each round of the game, the winner of the round is allowed to apply electrical stimulus to the opponent and is instructed to set the intensity of the applied pain (modulated by the number of electrical stimuli applied to the arm) to a value of his choosing. The test will be administered while the participant is inside an MRI scanner. A beltlike respiratory monitor will be affixed around the waist and a pulse oximeter will be clipped onto a finger or toe for physiological monitoring. Headphones are placed over the ears to remove MRI scanner noise and deliver audio stimuli during the task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Inhibitory Control Function</measure>
    <time_frame>days 9 (approximately), 37, and 56</time_frame>
    <description>The Multiple Source Interference Task will be administered while the participant is inside an MRI scanner. Each trial shows the participant a string of three numbers including digits 1 to 3, and requires the participant to use a 3-button response box to identify which of the three numbers appears only once in the string. There are two sources of interference: the two other distracting numbers in the string and positioning of the probe number that is discordant with the position of the corresponding button on the response box. A beltlike respiratory monitor will be affixed around the waist and a pulse oximeter will be clipped onto a finger or toe for physiological monitoring. Headphones are placed over the ears to remove MRI scanner noise and deliver audio stimuli during the task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Working Memory in Continuous Performance Task</measure>
    <time_frame>days 9 (approximately), 37, and 56</time_frame>
    <description>The AX continuous performance task requires individuals to click a response button when they observe an X that has been followed by an A in a stream of characters displayed on the screen. The test will be administered while the participant is inside an MRI scanner. A beltlike respiratory monitor will be affixed around the waist and a pulse oximeter will be clipped onto a finger or toe for physiological monitoring. Headphones are placed over the ears to remove MRI scanner noise and deliver audio stimuli during the task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Attentional and Inhibitory Control</measure>
    <time_frame>days 12 (approximately), 38, and 57</time_frame>
    <description>Participants will perform the Attention Network Task, in which they are presented with a line of arrows and required to click a lefthand or righthand button depending on whether the center arrow points to the left or right, respectively. The participant is required to suppress multiple distracting spatial cues to provide this correct response. The test will be administered while the participant is inside an MRI scanner. A beltlike respiratory monitor will be affixed around the waist and a pulse oximeter will be clipped onto a finger or toe for physiological monitoring. Headphones are placed over the ears to remove MRI scanner noise and deliver audio stimuli during the task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Emotional Reactivity</measure>
    <time_frame>days 12 (approximately), 38, and 57</time_frame>
    <description>Participants are presented with a series of trials in which a probe image of a human face shown in the center of the screen must be identified to a face shown either on the left or right side of the screen. The test will be administered while the participant is inside an MRI scanner. A beltlike respiratory monitor will be affixed around the waist and a pulse oximeter will be clipped onto a finger or toe for physiological monitoring. Headphones are placed over the ears to remove MRI scanner noise and deliver audio stimuli during the task.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Endocrine Mediators of Appetite</measure>
    <time_frame>days 7 and 43 and upon return to initial body weight, up to day 85</time_frame>
    <description>A fasted blood sample will be taken 15 minutes prior to a breakfast meal. Additional samples will be taken at 30, 60, 120, and 180 minutes after the meal on days 7 and 43 and at end of study. Samples also will be taken at 215, 245, 305, and 365 minutes after the meal on day 43. Serum will be analyzed for leptin and insulin, serum for glucose, and plasma for acyl ghrelin and des-acyl ghrelin. Additional samples will be collected and archived for future tests.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gut Microbiome Composition</measure>
    <time_frame>days 11-14, days 25-28, days 39-42, and upon return to initial body weight, up to day 85</time_frame>
    <description>A single fecal sample will be collected at each of 4 time points in the course of the study. Samples will be processed for analysis of gut microbiome composition.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Gastrointestinal Permeability</measure>
    <time_frame>days 11 and 39 and upon return to initial body weight, up to day 85</time_frame>
    <description>Participants will consume 2 g sucralose dissolved in 180 mL water. Sucralose is a sugar substitute commonly used as a sweetener in a variety of food products. Participants will then collect a urine sample 24 hours after sugar substitute ingestion. The sucralose ratio in the 24hr urine collection will provide measures of whole gut permeability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Eating Attitudes</measure>
    <time_frame>baseline, days 14 and 42, and upon return to initial body weight, up to day 85</time_frame>
    <description>Participants in a fasted state will complete the Food Cravings Questionnaire-trait and Food Cravings Inventory 2 to measure the frequency of cravings for specific types of foods.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Eating Behaviors</measure>
    <time_frame>baseline, days 14 and 42, and upon return to initial body weight, up to day 85</time_frame>
    <description>Participants in a fasted state will complete the Three Factor Eating Questionnaire to measure hunger, dietary restraint and disinhibition.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">53</enrollment>
  <condition>Caloric Restriction</condition>
  <condition>Exercise</condition>
  <arm_group>
    <arm_group_label>Energy Deficit</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants randomly assigned to the control condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered sesame oil placebo injections during phase 2 of the trial.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Energy Deficit + Testosterone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants randomly assigned to the intervention condition will be subject to exercise-induced energy expenditure resulting in a 55% energy deficit and will be administered testosterone enanthate injections during phase 2 of the trial.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sesame Oil</intervention_name>
    <description>200 mg sesame oil by intramuscular injection weekly on days 15, 21, 28, and 35</description>
    <arm_group_label>Energy Deficit</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>testosterone enanthate</intervention_name>
    <description>200 mg testosterone enanthate by intramuscular injection weekly on days 15, 21, 28, and 35</description>
    <arm_group_label>Energy Deficit + Testosterone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Physically active (at least 2 days per week aerobic and/or resistance exercise)

          -  Not taking any prescription medications and/or willing to refrain from all medication
             use prior to and throughout the entire study period, unless provided/approved by the
             study physician

          -  Willing to refrain from alcohol, smoking, e-cigarettes, or use of any nicotine
             product, caffeine, and dietary supplement use throughout the entire study period

               -  At the discretion of the study physician, wash-out period for medications,
                  supplements, and over-the-counter medications is ≥ 1 to 4 weeks

               -  Wash-out period for caffeine and alcohol is ≥ 7 days

          -  Willing to live on the Pennington Biomedical Research Center inpatient unit for 28
             consecutive days

          -  Willing to have a urine drug screening

          -  Meets age-specific U.S. Army body composition standards according to Army Regulation
             600-9, which includes estimates of percent body fat based on height, weight, and
             circumference measures (neck and waist)

          -  Total testosterone concentration is within the normal physiological range, total
             testosterone (300-1,000 ng/dL).

        Exclusion Criteria:

          -  Musculoskeletal injuries that compromise exercise capability

          -  Diagnosed cardiometabolic disorders (i.e., hypertension, hyperlipidemia, kidney
             disease, diabetes, etc.)

          -  Allergies or intolerance to foods, vegetarian practices, or history of complications
             with lidocaine

          -  Anabolic steroid, human growth hormone, or nutritional testosterone precursor-like
             supplement use within the past 6 months

          -  Will not refrain from smoking (any nicotine product), alcohol, caffeine, or any other
             dietary supplement during the study

          -  Any use of antibiotics, except topical antibiotics, within 3 months of study
             participation

          -  Colonoscopy within 3 months of study participation

          -  Chronic use of laxatives, stool softeners, antacids, or anti-diarrheal medications (≥
             once a week)

          -  History of gastrointestinal disease (e.g., celiac, irritable bowel syndrome, colitis,
             Crohn's disease)

          -  Restrained eater (the Three-Factor Eating Questionnaire) as assessed by the study's
             psychological and behavioral assessment staff

          -  Adults unable to consent

          -  Women

          -  Prisoners

          -  Metal implants, claustrophobia, head size incompatible with MRI equipment, etc.

          -  Sedentary or engages in &lt;2 days of physical activity per week (aerobic and/or
             resistance training)

          -  Exceeds age-specific U.S. Army body composition standards according to Army Regulation
             600-9

          -  Previous history of kidney stones unless otherwise approved by the medical
             investigator

          -  Systolic blood pressure &gt; 150 or diastolic blood pressure &gt; 95 mmHg

          -  Previous history of breast or prostate cancer

          -  Previous history of Chronic Obstructive Pulmonary Disease or Obstructive Sleep Apnea

          -  Findings of lab results of prostate-specific antigen &gt; 3ng/ml, Hematocrit &gt; 50%, or
             positive urine drug screening

          -  Based on the investigative team's clinical judgment, a subject may not be appropriate
             for participation in the study
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>39 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jennifer C Rood, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Pennington Biomedical Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pennington Biomedical Research Center</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>70808</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pasiakos SM, Margolis LM, Orr JS. Optimized dietary strategies to protect skeletal muscle mass during periods of unavoidable energy deficit. FASEB J. 2015 Apr;29(4):1136-42. doi: 10.1096/fj.14-266890. Epub 2014 Dec 30. Review.</citation>
    <PMID>25550460</PMID>
  </reference>
  <reference>
    <citation>Lieberman HR, Thompson LA, Caruso CM, Niro PJ, Mahoney CR, McClung JP, Caron GR. The catecholamine neurotransmitter precursor tyrosine increases anger during exposure to severe psychological stress. Psychopharmacology (Berl). 2015 Mar;232(5):943-51. doi: 10.1007/s00213-014-3727-7. Epub 2014 Sep 16.</citation>
    <PMID>25220844</PMID>
  </reference>
  <reference>
    <citation>Friedl KE, Moore RJ, Hoyt RW, Marchitelli LJ, Martinez-Lopez LE, Askew EW. Endocrine markers of semistarvation in healthy lean men in a multistressor environment. J Appl Physiol (1985). 2000 May;88(5):1820-30.</citation>
    <PMID>10797147</PMID>
  </reference>
  <reference>
    <citation>Opstad PK. The hypothalamo-pituitary regulation of androgen secretion in young men after prolonged physical stress combined with energy and sleep deprivation. Acta Endocrinol (Copenh). 1992 Sep;127(3):231-6.</citation>
    <PMID>1414148</PMID>
  </reference>
  <reference>
    <citation>Henning PC, Scofield DE, Spiering BA, Staab JS, Matheny RW Jr, Smith MA, Bhasin S, Nindl BC. Recovery of endocrine and inflammatory mediators following an extended energy deficit. J Clin Endocrinol Metab. 2014 Mar;99(3):956-64. doi: 10.1210/jc.2013-3046. Epub 2013 Dec 11.</citation>
    <PMID>24423293</PMID>
  </reference>
  <reference>
    <citation>Nindl BC, Friedl KE, Frykman PN, Marchitelli LJ, Shippee RL, Patton JF. Physical performance and metabolic recovery among lean, healthy men following a prolonged energy deficit. Int J Sports Med. 1997 Jul;18(5):317-24.</citation>
    <PMID>9298770</PMID>
  </reference>
  <reference>
    <citation>Nindl BC, Alemany JA, Kellogg MD, Rood J, Allison SA, Young AJ, Montain SJ. Utility of circulating IGF-I as a biomarker for assessing body composition changes in men during periods of high physical activity superimposed upon energy and sleep restriction. J Appl Physiol (1985). 2007 Jul;103(1):340-6. Epub 2007 Apr 5.</citation>
    <PMID>17412783</PMID>
  </reference>
  <reference>
    <citation>Carbone JW, McClung JP, Pasiakos SM. Skeletal muscle responses to negative energy balance: effects of dietary protein. Adv Nutr. 2012 Mar 1;3(2):119-26. doi: 10.3945/an.111.001792. Review.</citation>
    <PMID>22516719</PMID>
  </reference>
  <reference>
    <citation>Knapik JJ, Ang P, Meiselman H, Johnson W, Kirk J, Bensel C, Hanlon W. Soldier performance and strenuous road marching: influence of load mass and load distribution. Mil Med. 1997 Jan;162(1):62-7.</citation>
    <PMID>9002707</PMID>
  </reference>
  <reference>
    <citation>Knapik JJ, Reynolds KL, Harman E. Soldier load carriage: historical, physiological, biomechanical, and medical aspects. Mil Med. 2004 Jan;169(1):45-56. Review.</citation>
    <PMID>14964502</PMID>
  </reference>
  <reference>
    <citation>Roy TC. Diagnoses and mechanisms of musculoskeletal injuries in an infantry brigade combat team deployed to Afghanistan evaluated by the brigade physical therapist. Mil Med. 2011 Aug;176(8):903-8.</citation>
    <PMID>21882780</PMID>
  </reference>
  <reference>
    <citation>Roy TC, Ritland BM, Knapik JJ, Sharp MA. Lifting tasks are associated with injuries during the early portion of a deployment to Afghanistan. Mil Med. 2012 Jun;177(6):716-22.</citation>
    <PMID>22730849</PMID>
  </reference>
  <reference>
    <citation>Christensen PA, Jacobsen O, Thorlund JB, Madsen T, Møller C, Jensen C, Suetta C, Aagaard P. Changes in maximum muscle strength and rapid muscle force characteristics after long-term special support and reconnaissance missions: a preliminary report. Mil Med. 2008 Sep;173(9):889-94.</citation>
    <PMID>18816929</PMID>
  </reference>
  <reference>
    <citation>Alemany JA, Nindl BC, Kellogg MD, Tharion WJ, Young AJ, Montain SJ. Effects of dietary protein content on IGF-I, testosterone, and body composition during 8 days of severe energy deficit and arduous physical activity. J Appl Physiol (1985). 2008 Jul;105(1):58-64. doi: 10.1152/japplphysiol.00005.2008. Epub 2008 May 1.</citation>
    <PMID>18450989</PMID>
  </reference>
  <reference>
    <citation>Hoyt RW, Opstad PK, Haugen AH, DeLany JP, Cymerman A, Friedl KE. Negative energy balance in male and female rangers: effects of 7 d of sustained exercise and food deprivation. Am J Clin Nutr. 2006 May;83(5):1068-75.</citation>
    <PMID>16685048</PMID>
  </reference>
  <reference>
    <citation>Margolis LM, Rood J, Champagne C, Young AJ, Castellani JW. Energy balance and body composition during US Army special forces training. Appl Physiol Nutr Metab. 2013 Apr;38(4):396-400. doi: 10.1139/apnm-2012-0323. Epub 2013 Apr 3.</citation>
    <PMID>23713532</PMID>
  </reference>
  <reference>
    <citation>Nindl BC, Barnes BR, Alemany JA, Frykman PN, Shippee RL, Friedl KE. Physiological consequences of U.S. Army Ranger training. Med Sci Sports Exerc. 2007 Aug;39(8):1380-7.</citation>
    <PMID>17762372</PMID>
  </reference>
  <reference>
    <citation>Nindl BC, Rarick KR, Castellani JW, Tuckow AP, Patton JF, Young AJ, Montain SJ. Altered secretion of growth hormone and luteinizing hormone after 84 h of sustained physical exertion superimposed on caloric and sleep restriction. J Appl Physiol (1985). 2006 Jan;100(1):120-8. Epub 2005 Sep 1.</citation>
    <PMID>16141374</PMID>
  </reference>
  <reference>
    <citation>Nindl BC, Leone CD, Tharion WJ, Johnson RF, Castellani JW, Patton JF, Montain SJ. Physical performance responses during 72 h of military operational stress. Med Sci Sports Exerc. 2002 Nov;34(11):1814-22.</citation>
    <PMID>12439088</PMID>
  </reference>
  <reference>
    <citation>Welsh TT, Alemany JA, Montain SJ, Frykman PN, Tuckow AP, Young AJ, Nindl BC. Effects of intensified military field training on jumping performance. Int J Sports Med. 2008 Jan;29(1):45-52. Epub 2007 Sep 18.</citation>
    <PMID>17879876</PMID>
  </reference>
  <reference>
    <citation>Thorlund JB, Jakobsen O, Madsen T, Christensen PA, Nedergaard A, Andersen JL, Suetta C, Aagaard P. Changes in muscle strength and morphology after muscle unloading in Special Forces missions. Scand J Med Sci Sports. 2011 Dec;21(6):e56-63. doi: 10.1111/j.1600-0838.2010.01149.x. Epub 2010 Jun 18.</citation>
    <PMID>20561275</PMID>
  </reference>
  <reference>
    <citation>Areta JL, Burke LM, Camera DM, West DW, Crawshay S, Moore DR, Stellingwerff T, Phillips SM, Hawley JA, Coffey VG. Reduced resting skeletal muscle protein synthesis is rescued by resistance exercise and protein ingestion following short-term energy deficit. Am J Physiol Endocrinol Metab. 2014 Apr 15;306(8):E989-97. doi: 10.1152/ajpendo.00590.2013. Epub 2014 Mar 4.</citation>
    <PMID>24595305</PMID>
  </reference>
  <reference>
    <citation>Wycherley TP, Moran LJ, Clifton PM, Noakes M, Brinkworth GD. Effects of energy-restricted high-protein, low-fat compared with standard-protein, low-fat diets: a meta-analysis of randomized controlled trials. Am J Clin Nutr. 2012 Dec;96(6):1281-98. doi: 10.3945/ajcn.112.044321. Epub 2012 Oct 24. Review.</citation>
    <PMID>23097268</PMID>
  </reference>
  <reference>
    <citation>Pasiakos SM, Cao JJ, Margolis LM, Sauter ER, Whigham LD, McClung JP, Rood JC, Carbone JW, Combs GF Jr, Young AJ. Effects of high-protein diets on fat-free mass and muscle protein synthesis following weight loss: a randomized controlled trial. FASEB J. 2013 Sep;27(9):3837-47. doi: 10.1096/fj.13-230227. Epub 2013 Jun 5.</citation>
    <PMID>23739654</PMID>
  </reference>
  <reference>
    <citation>Pasiakos SM, Margolis LM, McClung JP, Cao JJ, Whigham LD, Combs GF, Young AJ. Whole-body protein turnover response to short-term high-protein diets during weight loss: a randomized controlled trial. Int J Obes (Lond). 2014 Jul;38(7):1015-8. doi: 10.1038/ijo.2013.197. Epub 2013 Oct 29.</citation>
    <PMID>24166063</PMID>
  </reference>
  <reference>
    <citation>Pasiakos SM, Austin KG, Lieberman HR, Askew EW. Efficacy and safety of protein supplements for U.S. Armed Forces personnel: consensus statement. J Nutr. 2013 Nov;143(11):1811S-1814S. doi: 10.3945/jn.113.176859. Epub 2013 Sep 11.</citation>
    <PMID>24027189</PMID>
  </reference>
  <reference>
    <citation>Margolis LM, Murphy NE, Martini S, Spitz MG, Thrane I, McGraw SM, Blatny JM, Castellani JW, Rood JC, Young AJ, Montain SJ, Gundersen Y, Pasiakos SM. Effects of winter military training on energy balance, whole-body protein balance, muscle damage, soreness, and physical performance. Appl Physiol Nutr Metab. 2014 Dec;39(12):1395-401. doi: 10.1139/apnm-2014-0212.</citation>
    <PMID>25386980</PMID>
  </reference>
  <reference>
    <citation>Bhasin S, Woodhouse L, Casaburi R, Singh AB, Bhasin D, Berman N, Chen X, Yarasheski KE, Magliano L, Dzekov C, Dzekov J, Bross R, Phillips J, Sinha-Hikim I, Shen R, Storer TW. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001 Dec;281(6):E1172-81.</citation>
    <PMID>11701431</PMID>
  </reference>
  <reference>
    <citation>Finkelstein JS, Yu EW, Burnett-Bowie SA. Gonadal steroids and body composition, strength, and sexual function in men. N Engl J Med. 2013 Dec 19;369(25):2457. doi: 10.1056/NEJMc1313169.</citation>
    <PMID>24350954</PMID>
  </reference>
  <reference>
    <citation>Kvorning T, Andersen M, Brixen K, Madsen K. Suppression of endogenous testosterone production attenuates the response to strength training: a randomized, placebo-controlled, and blinded intervention study. Am J Physiol Endocrinol Metab. 2006 Dec;291(6):E1325-32. Epub 2006 Jul 25.</citation>
    <PMID>16868226</PMID>
  </reference>
  <reference>
    <citation>Mauras N, Hayes V, Welch S, Rini A, Helgeson K, Dokler M, Veldhuis JD, Urban RJ. Testosterone deficiency in young men: marked alterations in whole body protein kinetics, strength, and adiposity. J Clin Endocrinol Metab. 1998 Jun;83(6):1886-92.</citation>
    <PMID>9626114</PMID>
  </reference>
  <reference>
    <citation>Henning PC, Margolis LM, McClung JP, Young AJ, Pasiakos SM. High protein diets do not attenuate decrements in testosterone and IGF-I during energy deficit. Metabolism. 2014 May;63(5):628-32. doi: 10.1016/j.metabol.2014.02.007. Epub 2014 Feb 17.</citation>
    <PMID>24641883</PMID>
  </reference>
  <reference>
    <citation>Murphy MG, Plunkett LM, Gertz BJ, He W, Wittreich J, Polvino WM, Clemmons DR. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism. J Clin Endocrinol Metab. 1998 Feb;83(2):320-5.</citation>
    <PMID>9467534</PMID>
  </reference>
  <reference>
    <citation>Clemmons DR, Smith-Banks A, Underwood LE. Reversal of diet-induced catabolism by infusion of recombinant insulin-like growth factor-I in humans. J Clin Endocrinol Metab. 1992 Jul;75(1):234-8.</citation>
    <PMID>1619015</PMID>
  </reference>
  <reference>
    <citation>Kupfer SR, Underwood LE, Baxter RC, Clemmons DR. Enhancement of the anabolic effects of growth hormone and insulin-like growth factor I by use of both agents simultaneously. J Clin Invest. 1993 Feb;91(2):391-6.</citation>
    <PMID>7679407</PMID>
  </reference>
  <reference>
    <citation>Dulloo AG, Jacquet J, Montani JP. How dieting makes some fatter: from a perspective of human body composition autoregulation. Proc Nutr Soc. 2012 Aug;71(3):379-89. doi: 10.1017/S0029665112000225. Epub 2012 Apr 5.</citation>
    <PMID>22475574</PMID>
  </reference>
  <reference>
    <citation>Dulloo AG, Jacquet J, Girardier L. Poststarvation hyperphagia and body fat overshooting in humans: a role for feedback signals from lean and fat tissues. Am J Clin Nutr. 1997 Mar;65(3):717-23.</citation>
    <PMID>9062520</PMID>
  </reference>
  <reference>
    <citation>Pescatello LS, Devaney JM, Hubal MJ, Thompson PD, Hoffman EP. Highlights from the functional single nucleotide polymorphisms associated with human muscle size and strength or FAMuSS study. Biomed Res Int. 2013;2013:643575. doi: 10.1155/2013/643575. Epub 2013 Dec 23.</citation>
    <PMID>24455711</PMID>
  </reference>
  <reference>
    <citation>Silverman I, Kastuk D, Choi J, Phillips K. Testosterone levels and spatial ability in men. Psychoneuroendocrinology. 1999 Nov;24(8):813-22.</citation>
    <PMID>10581652</PMID>
  </reference>
  <reference>
    <citation>Christiansen K, Knussmann R. Sex hormones and cognitive functioning in men. Neuropsychobiology. 1987;18(1):27-36.</citation>
    <PMID>3444523</PMID>
  </reference>
  <reference>
    <citation>Morley JE, Kaiser F, Raum WJ, Perry HM 3rd, Flood JF, Jensen J, Silver AJ, Roberts E. Potentially predictive and manipulable blood serum correlates of aging in the healthy human male: progressive decreases in bioavailable testosterone, dehydroepiandrosterone sulfate, and the ratio of insulin-like growth factor 1 to growth hormone. Proc Natl Acad Sci U S A. 1997 Jul 8;94(14):7537-42.</citation>
    <PMID>9207127</PMID>
  </reference>
  <reference>
    <citation>Moffat SD, Hampson E. A curvilinear relationship between testosterone and spatial cognition in humans: possible influence of hand preference. Psychoneuroendocrinology. 1996 Apr;21(3):323-37.</citation>
    <PMID>8817730</PMID>
  </reference>
  <reference>
    <citation>Muller M, Aleman A, Grobbee DE, de Haan EH, van der Schouw YT. Endogenous sex hormone levels and cognitive function in aging men: is there an optimal level? Neurology. 2005 Mar 8;64(5):866-71.</citation>
    <PMID>15753424</PMID>
  </reference>
  <reference>
    <citation>Beauchet O. Testosterone and cognitive function: current clinical evidence of a relationship. Eur J Endocrinol. 2006 Dec;155(6):773-81. Review.</citation>
    <PMID>17132744</PMID>
  </reference>
  <reference>
    <citation>Stanton SJ, Liening SH, Schultheiss OC. Testosterone is positively associated with risk taking in the Iowa Gambling Task. Horm Behav. 2011 Feb;59(2):252-6. doi: 10.1016/j.yhbeh.2010.12.003. Epub 2010 Dec 15.</citation>
    <PMID>21167166</PMID>
  </reference>
  <reference>
    <citation>Apicella CL, Dreber A, Mollerstrom J. Salivary testosterone change following monetary wins and losses predicts future financial risk-taking. Psychoneuroendocrinology. 2014 Jan;39:58-64. doi: 10.1016/j.psyneuen.2013.09.025. Epub 2013 Oct 6.</citation>
    <PMID>24275004</PMID>
  </reference>
  <reference>
    <citation>Coates JM, Gurnell M, Sarnyai Z. From molecule to market: steroid hormones and financial risk-taking. Philos Trans R Soc Lond B Biol Sci. 2010 Jan 27;365(1538):331-43. doi: 10.1098/rstb.2009.0193. Review.</citation>
    <PMID>20026470</PMID>
  </reference>
  <reference>
    <citation>Anderson RA, Martin CW, Kung AW, Everington D, Pun TC, Tan KC, Bancroft J, Sundaram K, Moo-Young AJ, Baird DT. 7Alpha-methyl-19-nortestosterone maintains sexual behavior and mood in hypogonadal men. J Clin Endocrinol Metab. 1999 Oct;84(10):3556-62.</citation>
    <PMID>10522995</PMID>
  </reference>
  <reference>
    <citation>O'Carroll R, Shapiro C, Bancroft J. Androgens, behaviour and nocturnal erection in hypogonadal men: the effects of varying the replacement dose. Clin Endocrinol (Oxf). 1985 Nov;23(5):527-38.</citation>
    <PMID>3910302</PMID>
  </reference>
  <reference>
    <citation>Skakkebaek NE, Bancroft J, Davidson DW, Warner P. Androgen replacement with oral testosterone undecanoate in hypogonadal men: a double blind controlled study. Clin Endocrinol (Oxf). 1981 Jan;14(1):49-61.</citation>
    <PMID>7014044</PMID>
  </reference>
  <reference>
    <citation>Salmimies P, Kockott G, Pirke KM, Vogt HJ, Schill WB. Effects of testosterone replacement on sexual behavior in hypogonadal men. Arch Sex Behav. 1982 Aug;11(4):345-53.</citation>
    <PMID>7149969</PMID>
  </reference>
  <reference>
    <citation>Wang C, Swerdloff RS, Iranmanesh A, Dobs A, Snyder PJ, Cunningham G, Matsumoto AM, Weber T, Berman N; Testosterone Gel Study Group. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab. 2000 Aug;85(8):2839-53.</citation>
    <PMID>10946892</PMID>
  </reference>
  <reference>
    <citation>Wright ND, Bahrami B, Johnson E, Di Malta G, Rees G, Frith CD, Dolan RJ. Testosterone disrupts human collaboration by increasing egocentric choices. Proc Biol Sci. 2012 Jun 7;279(1736):2275-80. doi: 10.1098/rspb.2011.2523. Epub 2012 Feb 1.</citation>
    <PMID>22298852</PMID>
  </reference>
  <reference>
    <citation>Zak PJ, Kurzban R, Ahmadi S, Swerdloff RS, Park J, Efremidze L, Redwine K, Morgan K, Matzner W. Testosterone administration decreases generosity in the ultimatum game. PLoS One. 2009 Dec 16;4(12):e8330. doi: 10.1371/journal.pone.0008330.</citation>
    <PMID>20016825</PMID>
  </reference>
  <reference>
    <citation>Baker LA, Pearcey SM, Dabbs JM Jr. Testosterone, alcohol, and civil and rough conflict resolution strategies in lesbian couples. J Homosex. 2002;42(4):77-88.</citation>
    <PMID>12243486</PMID>
  </reference>
  <reference>
    <citation>Johnson RT, Breedlove SM. Human trust: testosterone raises suspicion. Proc Natl Acad Sci U S A. 2010 Jun 22;107(25):11149-50. doi: 10.1073/pnas.1005376107. Epub 2010 Jun 10.</citation>
    <PMID>20538975</PMID>
  </reference>
  <reference>
    <citation>van Honk J, Tuiten A, Verbaten R, van den Hout M, Koppeschaar H, Thijssen J, de Haan E. Correlations among salivary testosterone, mood, and selective attention to threat in humans. Horm Behav. 1999 Aug;36(1):17-24.</citation>
    <PMID>10433883</PMID>
  </reference>
  <reference>
    <citation>Luboshitzky R, Shen-Orr Z, Herer P. Middle-aged men secrete less testosterone at night than young healthy men. J Clin Endocrinol Metab. 2003 Jul;88(7):3160-6.</citation>
    <PMID>12843160</PMID>
  </reference>
  <reference>
    <citation>Penev PD. Association between sleep and morning testosterone levels in older men. Sleep. 2007 Apr;30(4):427-32.</citation>
    <PMID>17520786</PMID>
  </reference>
  <reference>
    <citation>Wittert G. The relationship between sleep disorders and testosterone in men. Asian J Androl. 2014 Mar-Apr;16(2):262-5. doi: 10.4103/1008-682X.122586. Review.</citation>
    <PMID>24435056</PMID>
  </reference>
  <reference>
    <citation>Ebstein RP, Israel S, Chew SH, Zhong S, Knafo A. Genetics of human social behavior. Neuron. 2010 Mar 25;65(6):831-44. doi: 10.1016/j.neuron.2010.02.020. Review.</citation>
    <PMID>20346758</PMID>
  </reference>
  <reference>
    <citation>Bartels M, Van den Berg M, Sluyter F, Boomsma DI, de Geus EJ. Heritability of cortisol levels: review and simultaneous analysis of twin studies. Psychoneuroendocrinology. 2003 Feb;28(2):121-37. Review.</citation>
    <PMID>12510008</PMID>
  </reference>
  <reference>
    <citation>van Winkel R, Stefanis NC, Myin-Germeys I. Psychosocial stress and psychosis. A review of the neurobiological mechanisms and the evidence for gene-stress interaction. Schizophr Bull. 2008 Nov;34(6):1095-105. doi: 10.1093/schbul/sbn101. Epub 2008 Aug 20. Review.</citation>
    <PMID>18718885</PMID>
  </reference>
  <reference>
    <citation>Uhart M, McCaul ME, Oswald LM, Choi L, Wand GS. GABRA6 gene polymorphism and an attenuated stress response. Mol Psychiatry. 2004 Nov;9(11):998-1006.</citation>
    <PMID>15197399</PMID>
  </reference>
  <reference>
    <citation>Zhang L, Rao F, Wessel J, Kennedy BP, Rana BK, Taupenot L, Lillie EO, Cockburn M, Schork NJ, Ziegler MG, O'Connor DT. Functional allelic heterogeneity and pleiotropy of a repeat polymorphism in tyrosine hydroxylase: prediction of catecholamines and response to stress in twins. Physiol Genomics. 2004 Nov 17;19(3):277-91. Epub 2004 Sep 14.</citation>
    <PMID>15367723</PMID>
  </reference>
  <reference>
    <citation>Sumithran P, Proietto J. The defence of body weight: a physiological basis for weight regain after weight loss. Clin Sci (Lond). 2013 Feb;124(4):231-41. doi: 10.1042/CS20120223. Review.</citation>
    <PMID>23126426</PMID>
  </reference>
  <reference>
    <citation>Montani JP, Schutz Y, Dulloo AG. Dieting and weight cycling as risk factors for cardiometabolic diseases: who is really at risk? Obes Rev. 2015 Feb;16 Suppl 1:7-18. doi: 10.1111/obr.12251. Review.</citation>
    <PMID>25614199</PMID>
  </reference>
  <reference>
    <citation>Cummings DE. Ghrelin and the short- and long-term regulation of appetite and body weight. Physiol Behav. 2006 Aug 30;89(1):71-84. Epub 2006 Jul 21. Review.</citation>
    <PMID>16859720</PMID>
  </reference>
  <reference>
    <citation>Liu J, Prudom CE, Nass R, Pezzoli SS, Oliveri MC, Johnson ML, Veldhuis P, Gordon DA, Howard AD, Witcher DR, Geysen HM, Gaylinn BD, Thorner MO. Novel ghrelin assays provide evidence for independent regulation of ghrelin acylation and secretion in healthy young men. J Clin Endocrinol Metab. 2008 May;93(5):1980-7. doi: 10.1210/jc.2007-2235. Epub 2008 Mar 18.</citation>
    <PMID>18349056</PMID>
  </reference>
  <reference>
    <citation>Asarian L, Geary N. Sex differences in the physiology of eating. Am J Physiol Regul Integr Comp Physiol. 2013 Dec;305(11):R1215-67. doi: 10.1152/ajpregu.00446.2012. Epub 2013 Jul 31. Review.</citation>
    <PMID>23904103</PMID>
  </reference>
  <reference>
    <citation>Greenman Y, Rouach V, Limor R, Gilad S, Stern N. Testosterone is a strong correlate of ghrelin levels in men and postmenopausal women. Neuroendocrinology. 2009;89(1):79-85. doi: 10.1159/000151768. Epub 2008 Aug 28.</citation>
    <PMID>18753737</PMID>
  </reference>
  <reference>
    <citation>Pagotto U, Gambineri A, Pelusi C, Genghini S, Cacciari M, Otto B, Castañeda T, Tschöp M, Pasquali R. Testosterone replacement therapy restores normal ghrelin in hypogonadal men. J Clin Endocrinol Metab. 2003 Sep;88(9):4139-43.</citation>
    <PMID>12970277</PMID>
  </reference>
  <reference>
    <citation>Jockenhövel F, Blum WF, Vogel E, Englaro P, Müller-Wieland D, Reinwein D, Rascher W, Krone W. Testosterone substitution normalizes elevated serum leptin levels in hypogonadal men. J Clin Endocrinol Metab. 1997 Aug;82(8):2510-3.</citation>
    <PMID>9253326</PMID>
  </reference>
  <reference>
    <citation>Lambert GP. Stress-induced gastrointestinal barrier dysfunction and its inflammatory effects. J Anim Sci. 2009 Apr;87(14 Suppl):E101-8. doi: 10.2527/jas.2008-1339. Epub 2008 Sep 12. Review.</citation>
    <PMID>18791134</PMID>
  </reference>
  <reference>
    <citation>Teshima CW, Meddings JB. The measurement and clinical significance of intestinal permeability. Curr Gastroenterol Rep. 2008 Oct;10(5):443-9. Review.</citation>
    <PMID>18799118</PMID>
  </reference>
  <reference>
    <citation>Baumgart DC, Dignass AU. Intestinal barrier function. Curr Opin Clin Nutr Metab Care. 2002 Nov;5(6):685-94. Review.</citation>
    <PMID>12394645</PMID>
  </reference>
  <reference>
    <citation>Forchielli ML, Walker WA. The effect of protective nutrients on mucosal defense in the immature intestine. Acta Paediatr Suppl. 2005 Oct;94(449):74-83.</citation>
    <PMID>16214770</PMID>
  </reference>
  <reference>
    <citation>McClung JP, Karl JP. Iron deficiency and obesity: the contribution of inflammation and diminished iron absorption. Nutr Rev. 2009 Feb;67(2):100-4. doi: 10.1111/j.1753-4887.2008.00145.x. Review.</citation>
    <PMID>19178651</PMID>
  </reference>
  <reference>
    <citation>Deplancke B, Vidal O, Ganessunker D, Donovan SM, Mackie RI, Gaskins HR. Selective growth of mucolytic bacteria including Clostridium perfringens in a neonatal piglet model of total parenteral nutrition. Am J Clin Nutr. 2002 Nov;76(5):1117-25.</citation>
    <PMID>12399288</PMID>
  </reference>
  <reference>
    <citation>Sonoyama K, Fujiwara R, Takemura N, Ogasawara T, Watanabe J, Ito H, Morita T. Response of gut microbiota to fasting and hibernation in Syrian hamsters. Appl Environ Microbiol. 2009 Oct;75(20):6451-6. doi: 10.1128/AEM.00692-09. Epub 2009 Aug 21.</citation>
    <PMID>19700553</PMID>
  </reference>
  <reference>
    <citation>Plaisancie P, Ducroc R, El Homsi M, Tsocas A, Guilmeau S, Zoghbi S, Thibaudeau O, Bado A. Luminal leptin activates mucin-secreting goblet cells in the large bowel. Am J Physiol Gastrointest Liver Physiol. 2006 Apr;290(4):G805-12. Epub 2006 Feb 2.</citation>
    <PMID>16455789</PMID>
  </reference>
  <reference>
    <citation>Ravussin Y, Koren O, Spor A, LeDuc C, Gutman R, Stombaugh J, Knight R, Ley RE, Leibel RL. Responses of gut microbiota to diet composition and weight loss in lean and obese mice. Obesity (Silver Spring). 2012 Apr;20(4):738-47. doi: 10.1038/oby.2011.111. Epub 2011 May 19.</citation>
    <PMID>21593810</PMID>
  </reference>
  <reference>
    <citation>Braniste V, Leveque M, Buisson-Brenac C, Bueno L, Fioramonti J, Houdeau E. Oestradiol decreases colonic permeability through oestrogen receptor beta-mediated up-regulation of occludin and junctional adhesion molecule-A in epithelial cells. J Physiol. 2009 Jul 1;587(Pt 13):3317-28. doi: 10.1113/jphysiol.2009.169300. Epub 2009 May 11.</citation>
    <PMID>19433574</PMID>
  </reference>
  <reference>
    <citation>Meng J, Mostaghel EA, Vakar-Lopez F, Montgomery B, True L, Nelson PS. Testosterone regulates tight junction proteins and influences prostatic autoimmune responses. Horm Cancer. 2011 Jun;2(3):145-56. doi: 10.1007/s12672-010-0063-1.</citation>
    <PMID>21761342</PMID>
  </reference>
  <reference>
    <citation>Markle JG, Frank DN, Mortin-Toth S, Robertson CE, Feazel LM, Rolle-Kampczyk U, von Bergen M, McCoy KD, Macpherson AJ, Danska JS. Sex differences in the gut microbiome drive hormone-dependent regulation of autoimmunity. Science. 2013 Mar 1;339(6123):1084-8. doi: 10.1126/science.1233521. Epub 2013 Jan 17.</citation>
    <PMID>23328391</PMID>
  </reference>
  <reference>
    <citation>Lohman TG, Harris M, Teixeira PJ, Weiss L. Assessing body composition and changes in body composition. Another look at dual-energy X-ray absorptiometry. Ann N Y Acad Sci. 2000 May;904:45-54. Review.</citation>
    <PMID>10865709</PMID>
  </reference>
  <reference>
    <citation>Coviello AD, Kaplan B, Lakshman KM, Chen T, Singh AB, Bhasin S. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008 Mar;93(3):914-9. Epub 2007 Dec 26.</citation>
    <PMID>18160461</PMID>
  </reference>
  <reference>
    <citation>Lakshman KM, Kaplan B, Travison TG, Basaria S, Knapp PE, Singh AB, LaValley MP, Mazer NA, Bhasin S. The effects of injected testosterone dose and age on the conversion of testosterone to estradiol and dihydrotestosterone in young and older men. J Clin Endocrinol Metab. 2010 Aug;95(8):3955-64. doi: 10.1210/jc.2010-0102. Epub 2010 Jun 9.</citation>
    <PMID>20534765</PMID>
  </reference>
  <reference>
    <citation>Mifflin MD, St Jeor ST, Hill LA, Scott BJ, Daugherty SA, Koh YO. A new predictive equation for resting energy expenditure in healthy individuals. Am J Clin Nutr. 1990 Feb;51(2):241-7.</citation>
    <PMID>2305711</PMID>
  </reference>
  <reference>
    <citation>Lo S, Russell JC, Taylor AW. Determination of glycogen in small tissue samples. J Appl Physiol. 1970 Feb;28(2):234-6.</citation>
    <PMID>5413312</PMID>
  </reference>
  <reference>
    <citation>Carbone JW, Margolis LM, McClung JP, Cao JJ, Murphy NE, Sauter ER, Combs GF Jr, Young AJ, Pasiakos SM. Effects of energy deficit, dietary protein, and feeding on intracellular regulators of skeletal muscle proteolysis. FASEB J. 2013 Dec;27(12):5104-11. doi: 10.1096/fj.13-239228. Epub 2013 Aug 21.</citation>
    <PMID>23965841</PMID>
  </reference>
  <reference>
    <citation>Spiering BA, Kraemer WJ, Vingren JL, Ratamess NA, Anderson JM, Armstrong LE, Nindl BC, Volek JS, Häkkinen K, Maresh CM. Elevated endogenous testosterone concentrations potentiate muscle androgen receptor responses to resistance exercise. J Steroid Biochem Mol Biol. 2009 Apr;114(3-5):195-9. doi: 10.1016/j.jsbmb.2009.02.005. Epub 2009 Feb 21.</citation>
    <PMID>19429451</PMID>
  </reference>
  <reference>
    <citation>Price JC, Holmes WE, Li KW, Floreani NA, Neese RA, Turner SM, Hellerstein MK. Measurement of human plasma proteome dynamics with (2)H(2)O and liquid chromatography tandem mass spectrometry. Anal Biochem. 2012 Jan 1;420(1):73-83. doi: 10.1016/j.ab.2011.09.007. Epub 2011 Sep 14.</citation>
    <PMID>21964502</PMID>
  </reference>
  <reference>
    <citation>Bray GA, Redman LM, de Jonge L, Covington J, Rood J, Brock C, Mancuso S, Martin CK, Smith SR. Effect of protein overfeeding on energy expenditure measured in a metabolic chamber. Am J Clin Nutr. 2015 Mar;101(3):496-505. doi: 10.3945/ajcn.114.091769. Epub 2015 Jan 14.</citation>
    <PMID>25733634</PMID>
  </reference>
  <reference>
    <citation>WEIR JB. New methods for calculating metabolic rate with special reference to protein metabolism. J Physiol. 1949 Aug;109(1-2):1-9.</citation>
    <PMID>15394301</PMID>
  </reference>
  <reference>
    <citation>Jéquier E, Acheson K, Schutz Y. Assessment of energy expenditure and fuel utilization in man. Annu Rev Nutr. 1987;7:187-208. Review.</citation>
    <PMID>3300732</PMID>
  </reference>
  <reference>
    <citation>Lieberman HR, Bathalon GP, Falco CM, Kramer FM, Morgan CA 3rd, Niro P. Severe decrements in cognition function and mood induced by sleep loss, heat, dehydration, and undernutrition during simulated combat. Biol Psychiatry. 2005 Feb 15;57(4):422-9.</citation>
    <PMID>15705359</PMID>
  </reference>
  <reference>
    <citation>Lieberman HR, Caruso CM, Niro PJ, Adam GE, Kellogg MD, Nindl BC, Kramer FM. A double-blind, placebo-controlled test of 2 d of calorie deprivation: effects on cognition, activity, sleep, and interstitial glucose concentrations. Am J Clin Nutr. 2008 Sep;88(3):667-76.</citation>
    <PMID>18779282</PMID>
  </reference>
  <reference>
    <citation>Butcher J, Graham J, Tellegen A, Dahlstrom W, Kaemmer B. Minnesota Multiphasic Personality Inventory-2 (MMPI-2): Manual for administration, scoring, and interpretation 2nd ed. Minneapolis, MN: University of Minnesota Press; 2001.</citation>
  </reference>
  <reference>
    <citation>Weiner IB, Greene RL. Handbook of Personality Assessment. Hoboken, NJ: Wiley; 2006.</citation>
  </reference>
  <reference>
    <citation>Spiro A, Butcher JN, Levenson RM, Aldwin CM, Bossé R. Change and stability in personality: A 5-year study of the MMPI-2 in older men. In: Butcher JN, ed. Fundamentals of MMPI-2: Research and application Minneapolis, MN: University of Minnesota Press; 2000:443-462.</citation>
  </reference>
  <reference>
    <citation>Keo-Meier CL, Herman LI, Reisner SL, Pardo ST, Sharp C, Babcock JC. Testosterone treatment and MMPI-2 improvement in transgender men: a prospective controlled study. J Consult Clin Psychol. 2015 Feb;83(1):143-56. doi: 10.1037/a0037599. Epub 2014 Aug 11.</citation>
    <PMID>25111431</PMID>
  </reference>
  <reference>
    <citation>Buss AH, Perry M. The aggression questionnaire. J Pers Soc Psychol. 1992 Sep;63(3):452-9.</citation>
    <PMID>1403624</PMID>
  </reference>
  <reference>
    <citation>O'Connor DB, Archer J, Wu FC. Effects of testosterone on mood, aggression, and sexual behavior in young men: a double-blind, placebo-controlled, cross-over study. J Clin Endocrinol Metab. 2004 Jun;89(6):2837-45.</citation>
    <PMID>15181066</PMID>
  </reference>
  <reference>
    <citation>McNair DM, Lorr M, Droppleman LF. Profile of Mood States Manual. San Diego, CA: Educational and Industrial Testing Service; 1971.</citation>
  </reference>
  <reference>
    <citation>Banderet LE, Lieberman HR. Treatment with tyrosine, a neurotransmitter precursor, reduces environmental stress in humans. Brain Res Bull. 1989 Apr;22(4):759-62.</citation>
    <PMID>2736402</PMID>
  </reference>
  <reference>
    <citation>Lieberman HR, Bathalon GP, Falco CM, et al. The Fog of War: Documenting Cognitive Decrements Associated with the Stress of Combat. 2002.</citation>
  </reference>
  <reference>
    <citation>Lieberman HR, Falco CM, Slade SS. Carbohydrate administration during a day of sustained aerobic activity improves vigilance, as assessed by a novel ambulatory monitoring device, and mood. Am J Clin Nutr. 2002 Jul;76(1):120-7.</citation>
    <PMID>12081825</PMID>
  </reference>
  <reference>
    <citation>Lieberman HR, Tharion WJ, Shukitt-Hale B, Speckman KL, Tulley R. Effects of caffeine, sleep loss, and stress on cognitive performance and mood during U.S. Navy SEAL training. Sea-Air-Land. Psychopharmacology (Berl). 2002 Nov;164(3):250-61. Epub 2002 Sep 5.</citation>
    <PMID>12424548</PMID>
  </reference>
  <reference>
    <citation>Shukitt-Hale B, Askew EW, Lieberman HR. Effects of 30 days of undernutrition on reaction time, moods, and symptoms. Physiol Behav. 1997 Oct;62(4):783-9.</citation>
    <PMID>9284498</PMID>
  </reference>
  <reference>
    <citation>Cardello AV, Schutz HG, Lesher LL, Merrill E. Development and testing of a labeled magnitude scale of perceived satiety. Appetite. 2005 Feb;44(1):1-13. Epub 2004 Nov 13. Review.</citation>
    <PMID>15604029</PMID>
  </reference>
  <reference>
    <citation>Lejuez CW, Read JP, Kahler CW, Richards JB, Ramsey SE, Stuart GL, Strong DR, Brown RA. Evaluation of a behavioral measure of risk taking: the Balloon Analogue Risk Task (BART). J Exp Psychol Appl. 2002 Jun;8(2):75-84.</citation>
    <PMID>12075692</PMID>
  </reference>
  <reference>
    <citation>Burnham TC. High-testosterone men reject low ultimatum game offers. Proc Biol Sci. 2007 Sep 22;274(1623):2327-30.</citation>
    <PMID>17613451</PMID>
  </reference>
  <reference>
    <citation>Baron-Cohen S, Wheelwright S, Hill J, Raste Y, Plumb I. The &quot;Reading the Mind in the Eyes&quot; Test revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry. 2001 Feb;42(2):241-51.</citation>
    <PMID>11280420</PMID>
  </reference>
  <reference>
    <citation>Prevost M, Carrier ME, Chowne G, Zelkowitz P, Joseph L, Gold I. The Reading the Mind in the Eyes test: validation of a French version and exploration of cultural variations in a multi-ethnic city. Cogn Neuropsychiatry. 2014;19(3):189-204. doi: 10.1080/13546805.2013.823859. Epub 2013 Aug 13.</citation>
    <PMID>23937473</PMID>
  </reference>
  <reference>
    <citation>Fine BJ, Kobrick JL, Lieberman HR, Marlowe B, Riley RH, Tharion WJ. Effects of caffeine or diphenhydramine on visual vigilance. Psychopharmacology (Berl). 1994 Mar;114(2):233-8.</citation>
    <PMID>7838913</PMID>
  </reference>
  <reference>
    <citation>Dinges DF, Powell JW. Microcomputer analyses of performance on a portable, simple, visual RT task during sustained operations. Vol 171985:652-655.</citation>
  </reference>
  <reference>
    <citation>Baddeley AD. A 3 min reasoning test based on grammatical transformation. Psychon Sci. 1968;10(10):341-342.</citation>
  </reference>
  <reference>
    <citation>Morgenthaler T, Alessi C, Friedman L, Owens J, Kapur V, Boehlecke B, Brown T, Chesson A Jr, Coleman J, Lee-Chiong T, Pancer J, Swick TJ; Standards of Practice Committee; American Academy of Sleep Medicine. Practice parameters for the use of actigraphy in the assessment of sleep and sleep disorders: an update for 2007. Sleep. 2007 Apr;30(4):519-29.</citation>
    <PMID>17520797</PMID>
  </reference>
  <reference>
    <citation>Vartanian O, Mandel DR, Duncan M. Money or life: Behavioral and neural context effects on choice under uncertainty. Journal of Neuroscience, Psychology, and Economics. 2011;4(1):25-36.</citation>
  </reference>
  <reference>
    <citation>Lotze M, Veit R, Anders S, Birbaumer N. Evidence for a different role of the ventral and dorsal medial prefrontal cortex for social reactive aggression: An interactive fMRI study. Neuroimage. 2007 Jan 1;34(1):470-8. Epub 2006 Oct 27.</citation>
    <PMID>17071110</PMID>
  </reference>
  <reference>
    <citation>Bush G, Shin LM. The Multi-Source Interference Task: an fMRI task that reliably activates the cingulo-frontal-parietal cognitive/attention network. Nat Protoc. 2006;1(1):308-13.</citation>
    <PMID>17406250</PMID>
  </reference>
  <reference>
    <citation>Carter CS, Braver TS, Barch DM, Botvinick MM, Noll D, Cohen JD. Anterior cingulate cortex, error detection, and the online monitoring of performance. Science. 1998 May 1;280(5364):747-9.</citation>
    <PMID>9563953</PMID>
  </reference>
  <reference>
    <citation>Goetz SM, Tang L, Thomason ME, Diamond MP, Hariri AR, Carré JM. Testosterone rapidly increases neural reactivity to threat in healthy men: a novel two-step pharmacological challenge paradigm. Biol Psychiatry. 2014 Aug 15;76(4):324-31. doi: 10.1016/j.biopsych.2014.01.016. Epub 2014 Jan 29.</citation>
    <PMID>24576686</PMID>
  </reference>
  <reference>
    <citation>Blundell J, de Graaf C, Hulshof T, Jebb S, Livingstone B, Lluch A, Mela D, Salah S, Schuring E, van der Knaap H, Westerterp M. Appetite control: methodological aspects of the evaluation of foods. Obes Rev. 2010 Mar;11(3):251-70. doi: 10.1111/j.1467-789X.2010.00714.x. Epub 2010 Jan 29. Review.</citation>
    <PMID>20122136</PMID>
  </reference>
  <reference>
    <citation>Kuczynski J, Lauber CL, Walters WA, Parfrey LW, Clemente JC, Gevers D, Knight R. Experimental and analytical tools for studying the human microbiome. Nat Rev Genet. 2011 Dec 16;13(1):47-58. doi: 10.1038/nrg3129. Review.</citation>
    <PMID>22179717</PMID>
  </reference>
  <reference>
    <citation>Caporaso JG, Lauber CL, Walters WA, Berg-Lyons D, Huntley J, Fierer N, Owens SM, Betley J, Fraser L, Bauer M, Gormley N, Gilbert JA, Smith G, Knight R. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. ISME J. 2012 Aug;6(8):1621-4. doi: 10.1038/ismej.2012.8. Epub 2012 Mar 8.</citation>
    <PMID>22402401</PMID>
  </reference>
  <reference>
    <citation>Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK, Fierer N, Peña AG, Goodrich JK, Gordon JI, Huttley GA, Kelley ST, Knights D, Koenig JE, Ley RE, Lozupone CA, McDonald D, Muegge BD, Pirrung M, Reeder J, Sevinsky JR, Turnbaugh PJ, Walters WA, Widmann J, Yatsunenko T, Zaneveld J, Knight R. QIIME allows analysis of high-throughput community sequencing data. Nat Methods. 2010 May;7(5):335-6. doi: 10.1038/nmeth.f.303. Epub 2010 Apr 11.</citation>
    <PMID>20383131</PMID>
  </reference>
  <reference>
    <citation>Possemiers S, Verthé K, Uyttendaele S, Verstraete W. PCR-DGGE-based quantification of stability of the microbial community in a simulator of the human intestinal microbial ecosystem. FEMS Microbiol Ecol. 2004 Sep 1;49(3):495-507. doi: 10.1016/j.femsec.2004.05.002.</citation>
    <PMID>19712298</PMID>
  </reference>
  <reference>
    <citation>Grootjans J, Thuijls G, Verdam F, Derikx JP, Lenaerts K, Buurman WA. Non-invasive assessment of barrier integrity and function of the human gut. World J Gastrointest Surg. 2010 Mar 27;2(3):61-9. doi: 10.4240/wjgs.v2.i3.61.</citation>
    <PMID>21160852</PMID>
  </reference>
  <reference>
    <citation>Stunkard AJ, Messick S. The three-factor eating questionnaire to measure dietary restraint, disinhibition and hunger. J Psychosom Res. 1985;29(1):71-83.</citation>
    <PMID>3981480</PMID>
  </reference>
  <reference>
    <citation>Weiner C. Anticipate and communicate: Ethical management of incidental and secondary findings in the clinical, research, and direct-to-consumer contexts (December 2013 report of the Presidential Commission for the Study of Bioethical Issues). Am J Epidemiol. 2014 Sep 15;180(6):562-4. doi: 10.1093/aje/kwu217. Epub 2014 Aug 22.</citation>
    <PMID>25150271</PMID>
  </reference>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 31, 2016</study_first_submitted>
  <study_first_submitted_qc>April 5, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 12, 2016</study_first_posted>
  <last_update_submitted>January 30, 2018</last_update_submitted>
  <last_update_submitted_qc>January 30, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Pennington Biomedical Research Center</investigator_affiliation>
    <investigator_full_name>Jennifer C. Rood</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Testosterone</mesh_term>
    <mesh_term>Testosterone enanthate</mesh_term>
    <mesh_term>Testosterone undecanoate</mesh_term>
    <mesh_term>Testosterone 17 beta-cypionate</mesh_term>
    <mesh_term>Methyltestosterone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

